A Study To Assess The Efficacy And Safety Of Bismuth Tripotassium Dicitrate (De-Nol) In Combination With Pantoprazole And Pantoprazole Monotherapy In Treatment Of Subjects With Nonsteroidal Anti-Inflammatory Drugs (NSAID)-Induced Gastropathy (BiGARD)
Phase IV, Multicenter, Open Label, Randomized Study in Parallel Groups To Assess The Efficacy And Safety Of Bismuth Tripotassium Dicitrate (De-Nol®) In Combination With Pantoprazole And Pantoprazole Monotherapy In Treatment Of Patients With NSAID Induced Gastropathy
Sponsor: Astellas Pharma Europe B.V.
Terminated
Internal reassessment of the medicinal product development strategy by Sponsor
Other terminated trials from Astellas Pharma Europe B.V.
A PHASE4 clinical study on NSAID-induced Gastropathy, this trial is terminated or withdrawn. The trial is conducted by Astellas Pharma Europe B.V. and has accumulated 9 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE4
▶ Show 4 earlier versions
-
Oct 2017 — Jun 2018 [monthly]
Terminated PHASE4
Status: Recruiting → Terminated
-
May 2017 — Oct 2017 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Apr 2017 — May 2017 [monthly]
Not Yet Recruiting PHASE4
-
Jan 2017 — Apr 2017 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Astellas Pharma Europe B.V.
For direct contact, visit the study record on ClinicalTrials.gov .